Cargando…

Integrin Inhibitors in Prostate Cancer

Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Juan-Rivera, Maylein C., Martínez-Ferrer, Magaly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836076/
https://www.ncbi.nlm.nih.gov/pubmed/29415418
http://dx.doi.org/10.3390/cancers10020044
_version_ 1783303908142088192
author Juan-Rivera, Maylein C.
Martínez-Ferrer, Magaly
author_facet Juan-Rivera, Maylein C.
Martínez-Ferrer, Magaly
author_sort Juan-Rivera, Maylein C.
collection PubMed
description Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells.
format Online
Article
Text
id pubmed-5836076
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58360762018-03-07 Integrin Inhibitors in Prostate Cancer Juan-Rivera, Maylein C. Martínez-Ferrer, Magaly Cancers (Basel) Review Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells. MDPI 2018-02-06 /pmc/articles/PMC5836076/ /pubmed/29415418 http://dx.doi.org/10.3390/cancers10020044 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Juan-Rivera, Maylein C.
Martínez-Ferrer, Magaly
Integrin Inhibitors in Prostate Cancer
title Integrin Inhibitors in Prostate Cancer
title_full Integrin Inhibitors in Prostate Cancer
title_fullStr Integrin Inhibitors in Prostate Cancer
title_full_unstemmed Integrin Inhibitors in Prostate Cancer
title_short Integrin Inhibitors in Prostate Cancer
title_sort integrin inhibitors in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836076/
https://www.ncbi.nlm.nih.gov/pubmed/29415418
http://dx.doi.org/10.3390/cancers10020044
work_keys_str_mv AT juanriveramayleinc integrininhibitorsinprostatecancer
AT martinezferrermagaly integrininhibitorsinprostatecancer